Rombox

Quick links to important sections

Rombox

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rombox

Property Description
Active ingredient Ambroxol hydrochloride, Cephalexin
Form Film-coated tablets, Capsule, Syrup, Suspension
Pharmacological class Fixed-Dose Combination, Antibiotic, Mucolytic Agent
Common use Addressing bacterial infection and respiratory mucus impairment
Origin Semi-synthetic (Cephalexin), Synthetic derivative (Ambroxol)

Rombox: Definition and Pharmacological Classification

Rombox is defined as a specialized fixed-dose combination product, intentionally pairing two active pharmacological substances to address multiple aspects of a respiratory condition. This medicine belongs to the class of antibiotics and the class of mucolytic agents. The cephalosporin antibiotic component, Cephalexin, is clinically recognized for its bactericidal effectiveness against susceptible pathogens. Rombox is formulated for oral administration, utilizing forms such as film-coated tablets, capsules, or syrup for systemic delivery of both agents simultaneously.

Composition, Origin, and Dual Action Principle

The composition of Rombox relies on the synergistic potential of its components. The first active ingredient, Cephalexin, is a first-generation cephalosporin antibiotic, which is primarily responsible for the bactericidal action—it works to eliminate susceptible bacterial pathogens. The second agent, Ambroxol, a synthetic derivative, functions as a secretolytic and mucokinetic agent that liquefies and promotes the movement of abnormal respiratory secretions. Pharmacological studies have indicated that Ambroxol may assist in enhancing the concentration of the antibiotic, Cephalexin, within respiratory secretions. This suggests the mucolytic helps the antibiotic reach the infection site more effectively.

General Purpose of Rombox

The general purpose of Rombox is to offer an integrated approach to managing conditions where both a bacterial cause and a significant impairment in mucociliary clearance are present. By combining a targeted antibacterial agent with a compound that helps thin secretions and restore physiological transport mechanisms, the medicine aims to resolve the underlying infection while effectively alleviating the congestion and obstruction caused by thick mucus. The mucolytic component's ability to reduce mucus viscosity is a property supported by research. This action helps make breathing easier by clearing the airways during a period of infection.

Regulatory References

  1. Ambroxol and bromhexine-containing medicines - referral (EMA)

What side effects are possible with Rombox?

Official Safety Profile and Adverse Reactions

The safety profile for Rombox, based on governmental regulatory classifications, is defined by its inherent chemical hazards rather than a traditional therapeutic adverse reaction frequency schedule. This substance is formally designated with serious and clinically significant acute toxicity and irritation risks.

Key Hazard Classifications (GHS/CLP Framework):

Classification Category Regulatory Status (H-Statements) Population Focus
Acute Toxicity (Inhaled) Category 3 (Toxic) Occupational (Inhalation risk)
Acute Toxicity (Oral) Category 4 (Harmful) General/Accidental Exposure
Skin & Eye Hazard Skin Irritation 2, Eye Irritation 2 Direct Contact
Environmental Hazard Chronic Aquatic Toxicity 2 Environmental Release

Serious and clinically significant reactions include effects from inhalation or ingestion and corrosive effects on the skin and eyes. Due to its classification, strict limitations are placed on handling, including the mandatory use of Personal Protective Equipment (PPE) and measures to avoid breathing dust/fume/mist/vapours. The regulatory texts explicitly warn against release to the environment.

High-Level Safety Monitoring Notes

Official documents emphasize that exposure requires immediate removal to fresh air (if inhaled) and rinsing for several minutes if eye contact occurs. This underscores the potential for rapid onset of harm upon acute exposure. The regulatory basis is European Union's CLP Regulation, which uses GHS hazard statements and signal words such as Danger to structure the understanding of risks, rather than common/rare frequency bands used for prescribed medications.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Rombox overdose is based on the documented toxicities of both Cephalexin and Ambroxol. Overdose may present with common gastrointestinal symptoms, including nausea, vomiting, diarrhea, and stomach pain. Other documented manifestations are short-term restlessness, excessive saliva secretion, and the presence of pink, red, or dark brown urine.

Life-threatening outcomes are officially recognized. These include the potential for seizures associated with the Cephalexin component, particularly in patients with unreduced dosage and renal impairment, and hypotension (low blood pressure) documented in cases of extreme Ambroxol overdosage. Patients with severe liver impairment also face a documented risk of decreased drug elimination.

Situation Mandated Action
Suspected Overdose Contact a Poison Control Helpline for guidance.
Urgent Medical Emergency Immediately call emergency services (911) if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Treatment is primarily symptomatic and supportive, as no specific antidote is known for the active components. Procedural measures like gastric lavage are generally not indicated but may be considered only in documented cases of extreme overdose and within the first one to two hours of ingestion.

Therapeutic Uses of Rombox

What Rombox Treats: Main Uses and Benefits

Rombox is commonly used across conditions characterized by periods of heightened symptoms where a bacterial respiratory infection coincides with significant mucus pathology. For instance, the active antibiotic component is applied in addressing respiratory tract infections. This combination is considered relevant for infections such as acute exacerbations of chronic bronchitis, pneumonia, otitis media, or pharyngitis, where a susceptible bacterial cause is identified.

The medicine assists in addressing the bacterial cause, which is considered relevant in the management of the illness. It is also relevant for managing symptoms related to physical discomfort caused by thick, sticky, or excessive mucus. The combination contributes to improved comfort and is relevant for easing airway congestion and obstruction. This therapeutic support assists the patient during difficult episodes.

“This medication is applied in scenarios where additional management of discomfort is required because the clinical presentation needs the simultaneous addressing of the bacterial agent and assistance in clearing viscid secretions.”

The combined action helps patients cope more steadily with symptom fluctuations and is applied in clinical settings that involve acute or unstable symptom patterns. This provides support for productive cough and congestion.

Quick Fact: This medicine is relevant for easing symptoms that interfere with daily functioning, such as respiratory congestion and cough associated with infection.

Eligibility and Restrictions for Use

Who Can and Cannot Use Rombox?

The population eligibility for Rombox is strictly defined by regulatory documentation for its combined active components (Ambroxol and Cephalexin).


Contraindications

Rombox must not be used by certain populations, as they are formally contraindicated:

  • Patients with a known hypersensitivity to the active ingredients (Cephalexin or Ambroxol), other cephalosporin-class antibiotics, or any excipients.
  • Children under 2 years of age.
  • Individuals with rare hereditary problems of fructose intolerance (applies to certain excipient-containing formulations).

Restricted and Conditional Use

Use of Rombox is permitted only under specific conditions or with caution for the following groups:

  • Organ Impairment: Patients with renal impairment or severe hepatic impairment require close monitoring.
  • Allergy History: Individuals with a history of penicillin allergy should only use the medicine with caution due to the risk of cross-hypersensitivity.
  • Pregnancy: The medicine is not recommended for women during the first trimester of pregnancy.
  • Lactation: Use during lactation requires caution.
  • Age Groups: The medicine is eligible for use in adults and children aged 2 years and older. Older adults are eligible, but caution is advised due to the increased probability of age-related decreased renal function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Rombox, a fixed-dose combination of Cephalexin and Ambroxol, is officially structured around pharmacokinetic and pharmacodynamic restrictions, as documented in regulatory labeling.

Interaction Scope

Property Value
Medicinal product categories with documented interactions Agents that suppress the cough reflex (Antitussive Agents); Medicines that inhibit renal clearance (Uricosuric agents).
Specific interacting medicines (if explicitly listed) Probenecid.
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic interaction via inhibition of renal clearance; Pharmacodynamic interaction (additive effect on bronchial secretions).
Interaction-related restrictions Restriction on co-administration with Probenecid; Warning against concurrent use with Antitussive Agents.

Resulting Interaction Structure

The most significant official interaction statements relate to the systemic exposure of the antibiotic component and the function of the mucolytic component. Co-administration with Probenecid results in a pharmacokinetic interaction that increases the plasma exposure (AUC and C max) of the Cephalexin component by inhibiting its renal clearance. Additionally, concurrent use with Antitussive Agents is associated with a pharmacodynamic interaction that poses a risk of accumulating bronchial secretions, due to the mucolytic component's action combined with an inhibited cough reflex. Regulatory labels do not document clinically significant Cytochrome P450 (CYP) enzyme interactions that require specific restrictions. No mandatory timing separation rules are documented.

Mechanism of Action

Molecular and Physiological Mechanism of Action

The two active components of this medicine exert coordinated pharmacological effects through distinct mechanistic domains. The first component operates as an irreversible inhibitor of bacterial enzymes known as Penicillin-Binding Proteins (PBPs) . This targeted molecular action blocks the transpeptidation step necessary for constructing the bacterial cell wall, leading directly to the structural compromise and lysis of susceptible bacteria, resulting in bactericidal action against susceptible populations.

Simultaneously, the second component engages in the modulation of respiratory secretion dynamics. This is achieved by stimulating Type II pneumocytes and submucosal serous cells to increase the release of pulmonary surfactant and watery secretions. Furthermore, it promotes the depolymerization of acidic mucopolysaccharides. This alters the rheological properties of mucus, resulting in enhanced mucociliary clearance and the mobilization of abnormal secretions.

This two-part mechanism is characterized by mechanistic coordination, where the alteration of mucus viscosity facilitates the increased penetration and local concentration of the PBP inhibitor component within the infected respiratory tissue.

Dosage and Administration Information

How to Use Rombox

Rombox is an oral, fixed-dose combination product containing an antibiotic (Cephalexin) and a mucolytic agent, and its administration is strictly governed by the requirements of the antibiotic component. The medicine is delivered via the oral route, available in forms such as tablets, capsules, and liquid suspensions.

The standard administration regimen requires the medicine to be taken in divided doses throughout the day to ensure consistent therapeutic blood levels of the Cephalexin component. This typically means taking the medicine two to four times daily, such as 250 mg every 6 hours or 500 mg every 12 hours for adults, based on the infection's nature. The maximum dose for the antibiotic component is not to exceed 4 grams daily in divided doses.

Procedural and Time-Based Usage

The medicine may be taken with or without food as the antibiotic component is acid-stable and rapidly absorbed regardless of meals. For liquid suspension forms, the preparation must be shaken well before each dose to ensure accurate measurement.

The entire prescribed duration of therapy must be completed to ensure the eradication of the bacterial pathogen. The typical treatment duration is 7 to 14 days, with a minimum course of 10 days officially specified for infections caused by Beta-hemolytic streptococci.

Official prescribing information requires dose adjustment for certain patient populations. Specifically, the dosing interval or amount must be modified for adult patients who have significantly impaired renal function, typically defined as a Creatinine Clearance (CrCl) below 30 mL/min, to prevent drug accumulation. If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next dose; doses should not be doubled.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Rombox

Evidence for Use in Acute Exacerbations of Chronic Bronchitis (AECB)

Research exploring the Cephalexin and Ambroxol combination was evaluated in controlled, short-term trials for individuals experiencing an acute exacerbation of chronic bronchitis. These studies focused on conditions associated with acute or disruptive episodes where symptoms may vary in intensity. Researchers primarily monitored outcomes describing episodic or acute changes, along with outcomes monitoring physiological strain or stress, such as changes in lung function indicators. Some trials reported that findings describe patterns observed in the studies where the combination was compared against the antibiotic component given alone. Findings were mixed across studies.

What remains uncertain is that follow-up durations were limited to the acute treatment period. Long-term effects are not fully established, and there is limited information for long-term outcomes regarding the stability of the condition following treatment. The research includes studies where Ambroxol was associated with different antibiotics, not exclusively Cephalexin; the data for this specific combination is heterogeneous.


Evidence for Use in Bacterial Pharyngitis with Secretions

The combination was studied for bacterial throat infections, specifically in cases where conditions involving periods of heightened symptoms were also accompanied by increased mucus production. The research approach included controlled trials that explored comparisons of the fixed-dose combination to a single-drug treatment. Studies explored symptom changes over time and reported how symptoms evolved in the observed populations when the combination was compared to the antibiotic alone. This evidence contributes to understanding symptom patterns when the mucolytic agent is included in the treatment regimen for this specific presentation.

Evidence is limited for this indication because the body of research specifically for the Cephalexin/Ambroxol fixed-dose combination is limited compared to monotherapy data. Data for certain groups remain uncertain, especially for the pediatric population or older adults. Outcomes related to recurrence rates are not extensively characterized in the available research.


Research on Antibiotic Concentration and Delivery

These specialized studies, known as Pharmacokinetic (PK) studies, research examined the concentration of the antibiotic component in respiratory fluids, such as lung tissue and secretions, rather than focusing on patient-reported outcomes describing perceived discomfort. These findings show patterns related to drug levels, documenting that the presence of the mucolytic may influence the measured antibiotic concentration within the lung's airways. It is not yet clear whether the documented changes in drug concentration reliably translate into differences in patient-reported outcomes for the patient. The research primarily focuses on drug levels and does not provide insight into patient-reported symptom relief or long-term disease management.

Key Studies & References

  1. Cephalexin Drug Information (MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Rombox (FAQ)

Q: Is Rombox safe for long-term use?

A: Regulatory documents advise against using the antibiotic component for long periods without a confirmed bacterial infection due to the potential for drug-resistant bacteria to develop. Furthermore, official research overviews state that most clinical trials for this medicine had limited follow-up, meaning long-term effects are not fully established.


Q: Do the side effects of Rombox usually go away?

A: Official information indicates that some mild side effects, like nausea or headache, may lessen as the body adjusts to the medicine during the course of therapy. Other effects, such as diarrhea, have been described in some regulatory documents as potentially resolving after the medicine is discontinued.


Q: Does Rombox cause drowsiness or affect driving?

A: The official product information lists drowsiness or dizziness as potential, though less common, side effects of the antibiotic component. Because of potential effects on the central nervous system, regulatory labels generally include a caution that performing activities requiring alertness, such as driving or operating machinery, may be affected.


Q: Is it okay for people with kidney problems to use Rombox?

A: Official documentation describes use in patients with kidney problems as being permitted under specific conditions. Patients with renal impairment (kidney problems) are eligible for use but require close monitoring. In cases of significantly impaired kidney function, regulatory requirements describe that a modification of the dose is typically necessary to prevent the medicine from accumulating in the body.


Q: Can Rombox affect blood pressure?

A: Changes in blood pressure are not commonly listed as a direct adverse reaction in the official product information for Rombox. However, general warnings associated with the antibiotic component advise caution for people with high blood pressure who are taking certain other medications.


Q: Does Rombox interact with birth control pills?

A: While the primary interactions listed do not involve contraceptives, official information related to the antibiotic component, Cephalexin, has in some cases been linked to a potential reduction in the effectiveness of birth control pills containing ethinyl estradiol. This may be associated with an increased risk of breakthrough bleeding or potential contraceptive failure.


Q: Can Rombox be taken with antacids?

A: The official interaction statements do not list most common antacids as a restricted combination. Official recommendations state that oral products containing zinc (such as some mineral supplements) should be separated by at least 3 hours from the Rombox dose, as they may reduce the amount of the antibiotic absorbed by the body.


Q: Does Rombox have a risk of dependence or addiction?

A: No. Official regulatory bodies, such as the U.S. Drug Enforcement Administration (DEA), classify the antibiotic component as a non-scheduled drug. This classification means the medicine does not pose a risk of dependence or addiction.


Q: Can I take Rombox if I have a history of liver issues?

A: Patients with a history of severe hepatic impairment (serious liver issues) are required by regulatory documents to be closely monitored during treatment. Caution is generally advised because reduced liver function may increase the potential for adverse reactions.


Q: Why is Rombox only available by prescription?

A: The medicine is classified as a Prescription-Only Medicine (POM) primarily because it contains an antibiotic. Antibiotics require medical oversight to ensure they are used correctly to treat a confirmed bacterial infection, which helps to reduce the development of drug-resistant bacteria.


Q: Are there any known interactions between Rombox and herbal supplements?

A: Official interaction statements focus on prescription medicines, and there is generally not enough data to confirm the safety of taking most herbal remedies concurrently. Official recommendations state that oral products containing zinc should be separated by at least 3 hours from the Rombox dose, as they may reduce the amount of the antibiotic absorbed by the body.


Q: How long after stopping Rombox does it stay in the body?

A: Official pharmacokinetic studies provide estimates for the rate at which the active components are eliminated. The Ambroxol (mucolytic) component has an estimated half-life of about 10 hours. Most of the antibiotic component, Cephalexin, is generally excreted by the kidneys within 6 to 8 hours of administration.


Q: Is Rombox safe for use in children?

A: The official prescribing information states that Rombox is contraindicated (must not be used) in children under 2 years of age. It is eligible for use in children aged 2 years and older, with the dosage for this population being defined in the prescribing information.


Q: Why do some people need a higher strength of Rombox than others?

A: Dosage variations are based on official prescribing guidelines to ensure the appropriate concentration of the antibiotic is delivered. The required dose is primarily determined by the type and severity of the infection being treated. Regulatory information also specifies that the dose may need modification for adults with impaired renal function.


Q: Is Rombox used for chronic or acute conditions?

A: Research overviews describe the medicine being evaluated in clinical trials for acute exacerbations (sudden worsening) of chronic conditions, and for other infections involving acute or disruptive episodes. This suggests its primary studied use is in managing acute presentations of disease.


Q: What are the common signs of an allergic reaction to Rombox?

A: Official safety documentation lists potential signs of an allergic reaction to include rash, hives (urticaria), or swelling (angioedema). More severe, life-threatening reactions like anaphylaxis or severe skin conditions have also been reported with the antibiotic component.


Q: Does Rombox have specific warnings for people with diabetes?

A: The regulatory labels for the antibiotic component contain a specific warning about a potential interaction with the common diabetes medicine metformin. This interaction may increase the levels of metformin in the body, which may require monitoring and potential dose adjustment of the diabetes medicine.


Q: What does it mean if Rombox is classified as a 'Schedule' drug?

A: In the U.S., the 'Schedule' classification (controlled substance status) is used to regulate drugs with abuse potential. The antibiotic component of this medicine has a classification of DEA Schedule None, meaning it is not classified as a controlled substance and does not carry the associated risks of abuse.


Q: Are there any known interactions with alcohol for Rombox?

A: The official product label does not state a direct chemical interaction between the medicine and alcohol. However, official information notes that consuming alcohol may enhance some of the drug’s potential side effects, such as drowsiness or nausea, and may also affect the body's ability to recover from the infection.


Q: What remains uncertain in the research evidence?

A: Official reports explicitly list several areas of uncertainty regarding the combination medicine. These include the long-term effects on disease management, the limited follow-up duration in many trials, the heterogeneity of the data across studies, and whether changes in antibiotic concentration reliably translate into differences in patient-reported outcomes.


Q: Does Rombox affect fertility?

A: Nonclinical toxicology studies, which examined the antibiotic component in male and female rats, found that fertility and reproductive performance were not affected at doses up to 1.5 times the highest recommended human dose. The official product information does not list human fertility issues as a known side effect or warning.


Q: Is Rombox available as a generic medicine?

A: The antibiotic component, Cephalexin, is widely available with a marketing status of Abbreviated New Drug Application (ANDA) in the U.S. This means that a generic version of the single antibiotic component is approved and available.


Q: Is it possible to become resistant to the effects of Rombox over time?

A: Official warnings state that using the antibiotic component without a confirmed bacterial infection greatly increases the risk of drug-resistant bacteria developing. Furthermore, not completing the full prescribed course of therapy increases the likelihood that the bacteria will not be fully eradicated and will develop resistance.


Q: What is the potential impact of Rombox on mood?

A: While not a common side effect, some unspecified reactions reported include changes in mood such as anxiety, irritability, or restlessness. In rare instances, changes in behavior have been reported with similar classes of antibiotics.

How should Rombox be stored and disposed of?

How to Store and Dispose of Rombox?

Regulatory requirements define specific storage conditions for Rombox to maintain stability. The tablets and capsules must be stored at Controlled Room Temperature, between 20 C and 25 C (68 F and 77 F). The liquid suspension requires refrigeration after mixing and must not be frozen.

All forms must be kept in their tightly closed container, protected from excess moisture, and stored out of the sight and reach of children.

The reconstituted liquid suspension has a strict shelf-life and must be discarded after 14 days.

Disposal of expired or unused medicine should prioritize a drug take-back program. Medicines must not be flushed down the toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rombox found in:

A-Z Index: